Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data form mouse partial hepatectomy in Kras mutant and Bap1 deleted / Kras mutant mice

ABSTRACT: Expression data form mouse partial hepatectomy in Kras mutant and Bap1 deleted / Kras mutant mice

PROVIDER: PRJNA761288 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data form mouse partial hepatectomy in Kras mutant and Bap1 deleted / Kras mutant mice

Project description:BAP1 is a nuclear deubiquitinating enzyme in the ubiquitin carboxyterminal-hydrolase subfamily that is involved in chromatin remodeling. It has been demonstrated to function as a tumor suppressor gene in multiple human malignancies. Molecular studies have found recurrent somatic mutations in BAP1 in intrahepatic cholangiocarcinoma. We have characterized the role of BAP1 in ICC development through a combination of whole genome ChIP-on-chip and transcriptional profiling of the mouse hepatic tumors. In this dataset, we include the expression data obtained from dissected mouse livers containing tumors using a gain-of-function mutation in KRAS (G12D), as well as loss-of-function mutation in BAP1. These data are used to obtain genes that are differentially expressed in response to Bap1 loss.

2021-11-29 | GSE183554 | GEO

BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors

Project description:Inactivating mutations of BAP1 are linked with an increased risk of developing metastasis in UM, but the roles of BAP1 in UM progression is unclear. To characterize BAP1’s functions in UM, we performed RNA sequencing on BAP1 wild-type and mutant UM cell lines. Gene set enrichment analysis showed that there is metabolic heterogeneity in BAP1 mutant UM cells based on their oxidative phosphorylation gene signature.

2021-02-08 | GSE149920 | GEO

Expression profiles of restoration of BAP1 in a BAP1 deficient cell line

Project description:RNA-seq of UPMM3 with restoration of BAP1 and BAP1 mutant proteins. Cell line UPMM3 contains a frameshift mutation in BAP1.

2018-01-31 | GSE97224 | GEO

Murine Kras mutant or Kras wildtype cancer cell lines

Project description:Comparison of gene expression in murine Kras mutant (LLC, AE17, MC38, FULA1) and Kras wildtype cell lines (B16F10, PANO2, CULA). First gene expression of benign cells and tissue ( BMDM, TEC, LUNG, BMMC) was subtracted from both Kras mutant or Kras wildtype gene expression profiles. Second Kras mutant gene expression was compared to Kras wildtype gene expression. Cell lines expressing genetically modified Kras gene were included in the analysis. Genetic modification was either done by overexpression of mutant KRAS harboring a G12C mutation or silencing with shRNA targeting Kras. shControl cell lines were used also as wildtype samples in different analysis presented in the manuscript except MC38 ( run on chip MoGene_1.0).

2022-05-02 | GSE130624 | GEO

RNA-seq analysis of BAP1 mutant and wild-type uveal melanoma cell lines

Project description:Inactivating mutations of BAP1 are associated with an increased risk of developing metastasis in uveal melanoma (UM), but the roles of BAP1 in UM progression is unclear. To characterize BAP1’s functions in UM, we performed RNA sequencing on BAP1 wild-type and mutant UM cell lines. Differential analysis revealed that BAP1 loss is associated with an upregulated gene expression profile of multiple cell adhesion molecules (CAMs), including E-cadherin (CDH1), cell adhesion molecule 1 (CADM1), and syndecan-2 (SDC2).

2022-04-25 | GSE181194 | GEO

Murine Kras mutant or Kras wildtype cancer cell lines

Project description:Murine Kras mutant or Kras wildtype cancer cell lines

| PRJNA540827 | ENA

The effects of mutant ASXL1 and BAP1 expression on hematopoietic cells

Project description:To identify target genes of mutant ASXL1 and BAP1 in hematopoietic cells, we performed RNA-seq using murine c-kit positive cells transduced with ASXL1-MT (MT) or ASXL1-MT-K351R (KR) together with vector or BAP1. Method：Murine c-kit positive bone marrow cells were transduced with ASXL1-MT (MT) or ASXL1-MT-K351R (KR) (coexpressing blastcidin resistant gene) together with vector or BAP1 (coexpressing puromycin resistant gene). After the selection with blasticidin and puromycin for three days, colony-forming cells were collected to extract RNA for RNA-seq analysis.

2018-05-25 | GSE114861 | GEO

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies

Project description:KRAS mutant cancers, which feature the activation of multiple phosphorylation signaling pathways, remain a major challenge for cancer therapy. This study provides a landscape of the proteomics and phosphoproteomics of KRAS mutant cancers by analyzing different KRAS mutant human cancer cell lines across different tissues types. By integrating multi-omics analysis, we identify different robust subsets, which recapitulate the histological, pathological and prognostic features of human cancers.

2021-06-23 | PXD026892 |

Mutant KRAS-associated proteome is mainly controled by exogenous factors

Project description:KRAS signaling has been extensively studied, yet the clarification between KRAS-autonomous and non-autonomous mechanisms are still less explored. Understanding how KRAS signaling and effects are affected by exogenous stimuli can provide valuable insights not only to understand resistance mechanisms that justify pathway inhibition failure, but also to uncover novel therapeutic targets for mutant KRAS patients. Hence, aiming at understanding KRAS-autonomous versus non autonomous mechanisms, we studied the response of two mutant KRAS colorectal cancer cell lines (HCT116 and LS174T) - control and KRAS silenced- to TGFβ1-activated fibroblasts secretome. By performing a total proteome analysis, we observed that TGFβ1-activated fibroblast-secreted factors triggered cell-line specific proteome alterations and that mutant KRAS governs approximately 1/3 of those alterations. Moreover, the analysis of the impact of exogenous factors on the modulation of KRAS proteome revealed that more than 2/3 of the KRAS-associated proteome is controlled in a KRAS-non-autonomous manner, dependent on the exogeneous factors, in both cell lines. This work highlights the context-dependency of KRAS-associated signaling and reinforces the importance of establishing more integrative models resembling the complexity of the tumor microenvironment to study KRAS-associated signals.

2022-04-06 | PXD030551 | Pride

Id1 in mutant KRAS lung adenocarcinoma

Project description:Id1 in mutant KRAS lung adenocarcinoma

| PRJNA427431 | ENA